.svg){kind=small}
Richmond Pharmacology is excited to attend the 2024 American HeartAssociation (AHA) Scientific Sessions in Philadelphia. This premier event incardiovascular science will bring together global leaders to present anddiscuss the latest innovations in cardiovascular research, prevention, andtreatment. The sessions will cover a wide range of topics, including basic,clinical, and population science.
To connect with our team during the event, please reach out to arrange ameeting.
For more information, visit the AHA Scientific Sessions 2024 website.
-min.jpg)
.jpg)
Latest news
Richmond Appoints Lisa Campbell as Director of Regulatory Strategy
April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read moreVon Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol
April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read moreEvents
Swiss Biotech Day 2025
5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event
